Study of Ibrutinib Combined With Venetoclax in Subjects With Mantle Cell Lymphoma (MCL)

NCT03112174 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

366

Enrollment

INDUSTRY

Sponsor class

Conditions

Mantle-Cell Lymphoma

Interventions

DRUG: Ibrutinib
DRUG: Venetoclax
DRUG: Placebo Oral tablet to match Venetoclax

Sponsor

Pharmacyclics LLC.

Collaborators

[object Object]